Manages moderate to severe pain associated with endometriosis. Sold as Orilissa. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Elagolix Sodium (sold as Orilissa), first approved Jul 23, 2018, with 3 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Orilissa | Part D | $2.9M | -7% | 471 |
| Role of Menopause in ThermoregulationMenopause, Aging · Penn State University | Phase 4 | Recruiting | Jan 29, 2025 |
| Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe PainEndometriosis · AbbVie | Phase 3 | Active, not recruiting | Apr 3, 2020 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA